MedTrace Logo

Type 2 Diabetes Glucose Biomarker Study With a Continuous Glucose Monitoring System

NCT04529239 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-03-29

No results posted yet for this study

Summary

Current gold standard methodologies for diagnosing type 2 diabetes (T2D) or prediabetes can be unreliable and inaccurate, and require the need for multiple different tests for comparison. It is possible that a simpler and more refined method of diagnosing T2D or prediabetes involves examining the proportional-integral (PI) control system of the body's glycemic function (i.e., a model of the glucose curve). The purpose of this research is to examine how well a PI model can diagnose nondiabetic, prediabetic, or diabetic patients based on glucose data gathered from a wearable glucose monitoring device.

Conditions

Interventions

DEVICE

Abbott Freestyle Libre Pro

Continuous glucose monitoring device to analyze diabetes biomarkers.

Sponsors & Collaborators

  • Mittal Global Clinical Trial Services

    collaborator UNKNOWN

  • Klick Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-31
Primary Completion
2022-02-01
Completion
2022-03-01
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04529239 on ClinicalTrials.gov